迪瑞医疗(300396.SZ)公告称，持股12.15%的股东恒健国际计划以竞价或大宗交易方式减持公司股份总 数不超过8,148,270股，减持比例不超过公司总股本3%。 ...

证券代码：300396 证券简称：迪瑞医疗 公告编号：2025-020 迪瑞医疗科技股份有限公司 关于持股 5%以上股东减持股份预披露公告 持股 5%以上的股东广东恒健国际投资有限公司保证向本公司提供的信 息内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息 一致。 特别提示： 持有迪瑞医疗科技股份有限公司（以下简称"公司"）股份 33,123,600 股 （占公司总股本比例 12.15%）的股东广东恒健国际投资有限公司（以下简称"恒 健国际"）计划以竞价或大宗交易方式减持公司股份总数不超过 8,148,270 股， 减持比例不超过公司总股本 3%，自本减持计划公告之日起十五个交易日后的 90 日内实施。其中通过竞价方式减持的，任意连续 90 个自然日内减持公司股份总 数不超过 2,710,630 股，减持比例不超过公司总股本的 1%；通过大宗交易方式 减持的，任意连续 90 个自然日内减持公司股份不超过 5,437,640 股，减持比例 不超过公司总股本的 2%。 公司近日接到持股 5%以上股东恒健国际的通知，上述股东拟减持公司股票， 现 ...

最新一期业绩显示，2025年一季报，公司实现营业收入1.82亿元，同比-72.47%；净利润1567.87万元， 同比-87.13%，销售毛利率42.78%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)105迪瑞医疗101.0025.481.7536.16亿行业平均 48.9047.004.53103.78亿行业中值36.4137.242.4046.92亿1天益医疗-1685.63-2887.291.8021.48亿2澳华内 镜-613.48307.694.9164.65亿3诺唯赞-417.99-494.372.2989.45亿4博晖创新-329.61523.043.5248.36亿5爱朋 医疗-325.82247.533.9226.73亿6硕世生物-125.93-1840.221.1336.84亿7奥精医疗-117.01-171.501.5421.72亿 8睿昂基因-98.61-80.961.4012.76亿9康泰医学-84.98-71.803.0355.93亿10中红医疗-67.51-53.850.8546.92亿 11华大智造-63.30-56.174.36337.46亿 从行业市盈率排名来 ...

Investment Rating - The report maintains a "Recommendation" rating for the company, indicating an expectation to outperform the benchmark index by 10%-20% over the next six months [21]. Core Insights - The company reported Q1 2025 revenue of 182 million yuan, a decrease of 72.47% year-on-year, with a net profit of 16 million yuan, down 87.13% [1]. - The company is focusing on optimizing its reagent sales structure, with domestic reagent sales showing improvement and overseas operations remaining stable [7]. - The gross margin improved to 42.78%, up 6.38 percentage points year-on-year, while the net profit margin decreased to 8.59%, down 9.79 percentage points year-on-year due to increased expense ratios [7]. - The company expects a recovery in profits, projecting net profits of 200 million yuan, 260 million yuan, and 330 million yuan for 2025, 2026, and 2027, respectively, with corresponding growth rates of 41.7%, 27.4%, and 28.5% [7]. Financial Summary - Total revenue is projected to grow from 1,218 million yuan in 2024 to 2,018 million yuan in 2027, with year-on-year growth rates of -11.6%, 17.4%, 18.4%, and 19.3% [3]. - The earnings per share (EPS) are expected to increase from 0.52 yuan in 2024 to 1.21 yuan in 2027, with a corresponding price-to-earnings (P/E) ratio decreasing from 25 to 11 [3]. - The company’s total market capitalization is approximately 3.545 billion yuan, with a current share price of 13.00 yuan and a target price of 18.00 yuan [3][4].

迪瑞医疗科技股份有限公司《2025 年第一季度报告》于 2025 年 4 月 26 日 在中国证监会指定的创业板信息披露网站上披露，敬请投资者注意查阅。 特此公告。 迪瑞医疗科技股份有限公司董事会 证券代码：300396 证券简称：迪瑞医疗 公告编号：2025-019 迪瑞医疗科技股份有限公司 2025 年第一季度报告披露提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 2025 年 4 月 25 日 ...

Financial Performance - The company's revenue for Q1 2025 was ¥182,424,018.64, a decrease of 72.47% compared to ¥662,535,125.59 in the same period last year[5] - Net profit attributable to shareholders was ¥15,678,683.66, down 87.13% from ¥121,800,597.55 year-on-year[5] - Total operating revenue for the current period was ¥182,424,018.64, a significant decrease of 72.5% compared to ¥662,535,125.59 in the previous period[22] - Net profit for the current period was ¥15,677,203.80, a decrease of 87.1% compared to ¥121,793,477.11 in the previous period[23] - Basic and diluted earnings per share for the current period were both ¥0.0575, down from ¥0.4466 in the previous period[23] Cash Flow - The net cash flow from operating activities improved by 77.33%, reaching -¥41,723,517.67, compared to -¥184,049,664.39 in the previous year[5] - The net cash flow from operating activities was -41,723,517.67, an improvement from -184,049,664.39 in the previous period, indicating a reduction in cash outflow[25] - Cash inflow from operating activities totaled 208,512,287.80, down 27.2% from 286,322,068.49 in the prior period[25] - Cash outflow from operating activities decreased to 250,235,805.47 from 470,371,732.88, reflecting a 46.8% reduction[25] - The net cash flow from investing activities decreased by 116.94%, primarily due to the lack of new financial product purchases[13] - The net cash flow from investing activities was -2,795,904.72, compared to a positive cash flow of 16,503,423.86 in the previous period[25] - Cash inflow from investing activities was only 220.00, significantly lower than 174,288,796.33 in the prior period[25] - Cash outflow from investing activities decreased to 2,796,124.72 from 157,785,372.47, a reduction of 98.2%[25] - The net cash flow from financing activities was -153,126,702.55, worsening from -2,835,595.10 in the previous period[26] - Cash inflow from financing activities was 45,000,000.00, slightly down from 45,151,555.82 in the prior period[26] - Cash outflow from financing activities increased to 198,126,702.55 from 47,987,150.92, a rise of 313.5%[26] - The ending cash and cash equivalents balance was 389,760,256.23, down from 670,694,518.02 in the previous period[26] Assets and Liabilities - The total assets decreased by 6.83% to ¥2,895,358,808.01 from ¥3,107,533,388.27 at the end of the previous year[5] - Total current assets decreased from 1,844,110,841.82 yuan to 1,635,127,222.60 yuan, a decline of approximately 11.3%[19] - Cash and cash equivalents decreased from 586,680,294.87 yuan to 393,260,256.23 yuan, a decline of approximately 33.1%[19] - Total liabilities decreased to ¥825,581,940.55 from ¥1,058,764,060.35, a reduction of 22.0%[21] - The total equity attributable to shareholders of the parent company increased to ¥2,069,765,611.38 from ¥2,048,756,770.93, an increase of 1.0%[21] Shareholder Information - Total number of common shareholders at the end of the reporting period is 17,877[15] - The largest shareholder, Shenzhen Huade Xinrun Equity Investment Enterprise, holds 28.34% of shares, totaling 77,288,400 shares, with 45,600,156 shares pledged[15] - Guangdong Hengjian International Investment Co., Ltd. holds 12.15% of shares, totaling 33,123,600 shares[15] Operational Strategy - The company installed over 400 high-speed instruments in the domestic market during the first quarter, indicating a focus on increasing reagent sales[8] - The company adjusted its sales strategy in international markets, particularly focusing on Southeast Asia and Belt and Road Initiative countries[8] - The company plans to enhance operational efficiency by implementing cost-cutting measures and increasing reagent sales[8] Research and Development - Research and development expenses decreased by 34.09% to ¥2,100,000.00, due to optimized project spending[10] - Research and development expenses for the current period were ¥21,117,372.39, a decrease of 34.1% from ¥32,040,993.06 in the previous period[22] - The company has not disclosed any new product or technology developments in the current reporting period[18] Inventory and Receivables - Accounts receivable increased slightly from 441,690,051.18 yuan to 441,722,093.25 yuan[19] - Inventory decreased from 576,420,879.57 yuan to 559,041,927.84 yuan, a decline of approximately 3.0%[19] - Long-term equity investments increased from 450,858,277.53 yuan to 454,373,373.16 yuan[19] Other Financial Metrics - Operating costs decreased by 75.23% to ¥104,000,000.00, reflecting the reduction in revenue[10] - Total operating costs for the current period were ¥174,838,646.92, down 67.1% from ¥532,151,957.58 in the previous period[22] - The company reported a financial expense of -¥7,407,661.00, compared to a financial expense of ¥1,246,558.73 in the previous period, indicating a significant improvement[22] - Other comprehensive income after tax for the current period was ¥5,330,335.74, compared to ¥542,085.22 in the previous period, showing a substantial increase[23]

Company Overview - Di Rui Medical closed at 13.43 yuan on April 21, with an increase of 1.21%, and a rolling PE ratio of 25.81 times, resulting in a total market capitalization of 3.662 billion yuan [1] - The company ranks 64th in the medical device industry, which has an average PE ratio of 47.69 times and a median of 29.88 times [1][2] - Di Rui Medical specializes in the research, production, marketing, and service of medical testing instruments and related reagents, with key products including urine analysis, biochemical analysis, chemiluminescence immunoassay, gynecological secretion analysis, blood cell analysis, coagulation analysis, and overall laboratory solutions [1] Financial Performance - For the latest fiscal year 2024, Di Rui Medical reported a revenue of 1.218 billion yuan, a year-on-year decrease of 11.63%, and a net profit of 142 million yuan, down 48.50% year-on-year, with a gross profit margin of 43.84% [1] Capital Flow - On April 21, the net outflow of main funds for Di Rui Medical was 1.7783 million yuan, with a total outflow of 13.2825 million yuan over the past five days [1]

证券代码：300396 证券简称：迪瑞医疗 公告编号：2025-017 迪瑞医疗科技股份有限公司 2024 年年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决议案的情形； 2、本次股东大会未涉及变更前次股东大会决议； 一、会议召开和出席情况 公司于 2025 年 03 月 29 日发出《关于召开 2024 年年度股东大会的通知》 （详见中国证监会指定的创业板信息披露网站 http://www.cninfo.com.cn）。 1、会议召开时间：2025 年 04 月 18 日 14:30 2、会议召开地点：公司会议室 3、会议召开方式：采取现场投票与网络投票相结合的方式。现场会议召开 时间：2025 年 04 月 18 日（星期五）14:30。网络投票时间：2025 年 04 月 18 日。 其中，通过交易系统进行网络投票的时间为：2025 年 04 月 18 日（星期五）9:15— 9:25、9:30-11:30 和 13:00—15:00；通过互联网投票系统投票的具体时间为：2025 年 04 月 ...

致：迪瑞医疗科技股份有限公司（贵公司） 北京市东城区建国门内大街 26 号新闻大厦 7 层、8 层 电话：010-88004488/66090088 传真：010-66090016 邮编：100005 北京国枫律师事务所 关于迪瑞医疗科技股份有限公司 2024 年年度股东大会的 法律意见书 国枫律股字[2025]A0118号 北京国枫律师事务所（以下简称"本所"）接受贵公司的委托，指派律师出席并见证 贵公司 2024 年年度股东大会（以下简称"本次会议"）。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人 民共和国证券法》（以下简称"《证券法》"）、《上市公司股东大会规则》（以下简称 "《股东大会规则》"）、《律师事务所从事证券法律业务管理办法》（以下简称"《证券法 律业务管理办法》"）、《律师事务所证券法律业务执业规则（试行）》（以下简称"《证券法 律业务执业规则》"）等相关法律、行政法规、规章、规范性文件及《迪瑞医疗科技股份 有限公司章程》（以下简称"《公司章程》"）的规定，就本次会议的召集与召开程序、召 集人资格、出席会议人员资格、会议表决程序及表决结果等事宜，出具本法律意见书 ...

Core Viewpoint - The recent announcement by the U.S. government to impose "reciprocal tariffs" on Chinese goods has prompted a swift response from several medical device companies, which have indicated they have comprehensive plans and measures in place to address the situation. Despite the complex impacts on the supply chain, the long-term trend towards self-sufficiency and international expansion in the medical device sector remains optimistic [1][2][7]. Company Responses - Multiple medical device companies have reported minimal impact from the U.S. tariff policy, citing pre-existing contingency plans. For instance, Mindray Medical has proactively stocked products in the U.S. ahead of previous tariff increases, ensuring that current sales are unaffected by the new tariffs [2][8]. - Kaili Medical stated that the U.S. market contributes only 1%-2% to its revenue, and prior inventory preparations have mitigated the tariff impact. The company has a well-established overseas market presence [3][8]. - Dirui Medical anticipates that its direct exports to the U.S. will be around $150,000 in 2024, representing a negligible portion of its overall revenue. The company has also identified measures to minimize the tariff's effects [3]. - Leshi Medical indicated that the tariff impact is manageable, as its U.S. operations focus on digital chronic disease management solutions, which have established long-term customer relationships [3][8]. - Weili Medical reported that its exports to the U.S. account for about 15% of total revenue, with a stable business model due to long-term partnerships and necessary certifications [4]. Industry Trends - The Chinese medical device industry is experiencing a push towards domestic production and innovation, particularly in high-end medical imaging and core components, where reliance on imports has been significant. Recent advancements in domestic R&D are enabling some companies to gain competitive advantages [4][6]. - The Ministry of Commerce has initiated anti-dumping investigations into imported medical CT tubes, which may benefit domestic suppliers and manufacturers [5]. - The Chinese government continues to support the medical device sector, promoting high-quality development and encouraging companies to expand internationally. This includes backing for high-end medical devices and innovative technologies [6][7]. - Analysts suggest that despite the tariff challenges, there is a strong potential for domestic companies to increase market share and reduce reliance on imports, particularly in high-value consumables and in vitro diagnostics (IVD) sectors [7]. Long-term Outlook - The long-term export potential for Chinese medical device companies remains positive, with a focus on expanding into developing markets outside the U.S. Companies like Mindray Medical are looking to enhance their brand presence in these regions [8]. - Companies are diversifying their international strategies, with plans for local production and sales in emerging markets such as Mexico, which is expected to commence operations by early 2026 [8].